StockWatch: Will BMS–2seventy Deal Prove a Win-Win?
Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how competitive Abecma will continue to be in the multiple myeloma space given an existing blockbuster rival, and the prospect of a new competitor drug coming next year.